Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease

被引:126
作者
Lane, RM [1 ]
Farlow, MR
机构
[1] Novartis Pharmaceut, E Hanover, NJ 07936 USA
[2] Indiana Univ, Sch Med, Indianapolis, IN USA
关键词
long-chain polyunsaturated essential fatty acid; cholesterol; carbohydrate; lipid raft;
D O I
10.1194/jlr.M400486-JLR200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Extracellular amyloid plaques, intracellular neurofibrillary tangles, and loss of basal forebrain cholinergic neurons in the brains of Alzheimer's disease ( AD) patients may be the end result of abnormalities in lipid metabolism and peroxidation that may be caused, or exacerbated, by beta-amyloid peptide (A beta). Apolipoprotein E ( apoE) is a major apolipoprotein in the brain, mediating the transport and clearance of lipids and A beta. ApoE-dependent dendritic and synaptic regeneration may be less efficient with apoE4, and this may result in, or unmask, age-related neurodegenerative changes. The increased risk of AD associated with apoE4 may be modulated by diet, vascular risk factors, and genetic polymorphisms that affect the function of other transporter proteins and enzymes involved in brain lipid homeostasis. Diet and apoE lipoproteins influence membrane lipid raft composition and the properties of enzymes, transporter proteins, and receptors mediating A beta production and degradation, tau phosphorylation, glutamate and glucose uptake, and neuronal signal transduction. The level and isoform of apoE may influence whether A beta is likely to be metabolized or deposited. This review examines the current evidence for diet, lipid homeostasis, and apoE in the pathogenesis of AD. Effects on the cholinergic system and response to cholinesterase inhibitors by APOE allele carrier status are discussed briefly.
引用
收藏
页码:949 / 968
页数:20
相关论文
共 252 条
[21]   Brain cholesterol:: Long secret life behind a barrier [J].
Björkhem, I ;
Meaney, S .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (05) :806-815
[22]   Patterns of brain activation in people at risk for Alzheimer's disease [J].
Bookheimer, SY ;
Strojwas, MH ;
Cohen, MS ;
Saunders, AM ;
Pericak-Vance, MA ;
Mazziotta, JC ;
Small, GW .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (07) :450-456
[23]   The very high prevalence of AD in an Arab population is not explained by APOE ε4 allele frequency [J].
Bowirrat, A ;
Friedland, RP ;
Chapman, J ;
Korczyn, AD .
NEUROLOGY, 2000, 55 (05) :731-731
[24]   Can statins prevent AD, or are they just prescribed less often to those with cognitive disorders? [J].
Breitner, JCS ;
Zandi, PP ;
Li, G ;
Rea, TD ;
Psaty, BM .
NEUROBIOLOGY OF AGING, 2004, 25 :S5-S5
[25]   APOE-ε4 count predicts age when prevalence of AD increases, then declines -: The Cache County Study [J].
Breitner, JCS ;
Wyse, BW ;
Anthony, JC ;
Welsh-Bohmer, KA ;
Steffens, DC ;
Norton, MC ;
Tschanz, JT ;
Plassman, BL ;
Meyer, MR ;
Skoog, I ;
Khachaturian, A .
NEUROLOGY, 1999, 53 (02) :321-331
[26]  
Bullido MJ, 2000, MICROSC RES TECHNIQ, V50, P261, DOI 10.1002/1097-0029(20000815)50:4<261::AID-JEMT2>3.0.CO
[27]  
2-B
[28]  
Butterfield DA, 2002, NEUROBIOL AGING, V23, P655
[29]   Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model [J].
Calon, F ;
Lim, GP ;
Yang, FS ;
Morihara, T ;
Teter, B ;
Ubeda, O ;
Rostaing, P ;
Triller, A ;
Salem, N ;
Ashe, KH ;
Frautschy, SA ;
Cole, GM .
NEURON, 2004, 43 (05) :633-645
[30]  
CAMMER W, 1984, OLIGODENDROGLIA, P199